PRL3-Zumab

P2/3, N=52, Recruiting, Intra-IMMUSG Pte Ltd

P2, N=51, Active, not recruiting, Intra-IMMUSG Pte Ltd | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026

P1, N=38, Active, not recruiting, National University Hospital, Singapore | Unknown status --> Active, not recruiting | Trial completion date: Feb 2020 --> Feb 2027 | Trial primary completion date: Feb 2020 --> Feb 2027

PRL3-zumab, an anti-PRL3 humanized monoclonal antibody, has shown a strong safety profile in ongoing multi-national Phase II trials as an intravenous-administered cancer immunotherapeutic. PRL3's involvement in ocular pathological angiogenesis suggests the potential of repurposing PRL3-zumab to treat neovascular eye diseases.

Targeted therapies against PRL-3, encompassing small molecule inhibitors and the monoclonal antibody PRL-3-zumab, have shown promise in clinical and preclinical studies, presenting new avenues for cancer treatment. In addition, innovative approaches such as CAAX motif-targeting agents and PRL-3 degradation strategies hold promise for developing more precise and effective interventions. This review explores PRL-3's multifaceted roles across different tumor types and microenvironments, while discussing current and emerging therapeutic strategies aimed at exploiting its oncogenic potential.

P2, N=51, Active, not recruiting, Intra-IMMUSG Pte Ltd | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Nov 2025

P2, N=51, Active, not recruiting, Intra-IMMUSG Pte Ltd | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Dec 2024

PRL-3-zumab, a humanized antibody, shows promise in preclinical studies and clinical trials. Our review summarizes the current understanding of the cancer-related cellular function of PRL-3, its prognostic value, and the research progress of therapeutic inhibitors.

P2, N=30, Recruiting, National Cancer Centre, Singapore | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025

A 28.6% reduction in maximum target lesion diameter was achieved when PRL3-zumab was administered concurrently with hypofractionated radiation. These findings support wider exploration of PRL3 expression in embryonal and mesenchymal tumors and further clinical application of PRL3-zumab in pediatric patients.

PRL3-zumab, a first-in-class humanized antibody, was safe and tolerable in solid tumors and hematological malignancies.

PRL3-zumab has been approved for Phase 2 clinical trials in Singapore, US, and China to block all solid tumors. This study further showed PRL3-zumab could potentially serve an 'Adjuvant Immunotherapy' after tumor removal surgery to eliminate PRL3 PGCC stem-like cells, preventing metastasis and relapse.